Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration - Top-Institutions - MDSpire

Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration

  • By

  • Xiaobing Li

  • Xue Zeng

  • Xuemei Li

  • Yongsheng Liu

  • Junling Tang

  • Li Zhang

  • Limin Wei

  • Jingxin Mao

  • February 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cancer Pharmacology
    • Immuno-oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Cancer Biology
    • Pharmacology

  • #3

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Pharmacology
    • Immunology

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Cancer Pharmacology
    • Molecular Biology

  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Oncology
    • Cancer Pharmacology
    • Immunology

Original Source(s)

Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration

  • by Xiaobing Li, Xue Zeng, Xuemei Li, Yongsheng Liu, Junling Tang, Li Zhang, Limin Wei, Jingxin Mao

  • February 13, 2026

Related Content

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases